Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
August 22, 2025
WARREN, N.J., Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), announced today that it has been named in BINJE’s BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a media outlet covering business and politics across New Jersey, highlighted Tevogen Bio’s Founder and CEO, Ryan Saadi, MD, MPH, for his commitment to health equity and innovation in sustainable biopharma.
In its recognition, BINJE noted, “Driven by an unrelenting passion to advance the cause of health equity for all and the belief that societal prosperity and business success are intrinsically linked, Saadi has tirelessly strived to pave the way for a new era in the industry, one in which access to life-saving medications is more evenly distributed through a sustainable biopharma model.”
Tevogen Bio is focused on developing affordable, safe, and easy-to-administer T cell therapies for acute viral infections, the long-term effects of viral infections, and both viral and non-viral induced cancers. The Company’s proprietary ExacTcell™ platform enabled a proof-of-concept clinical trial with highly positive results, published in Blood Advances. Tevogen’s business model is designed to withstand current market pressures by operating a lean, capital-efficient structure that avoids licensing overhead through full ownership of its core intellectual property. Its off-the-shelf, genetically unmodified CD8+ T cell therapies aim to reduce manufacturing complexity and cost, aligning with U.S. healthcare priorities such as affordability, domestic production, and scalable innovation. A major milestone in Tevogen’s pursuit of accessibility was the launch of Tevogen.AI, which leverages advanced algorithms and a strategic partnership with Microsoft and Databricks to accelerate therapeutic discovery and development.
Tevogen extends its gratitude to BINJE and its founder and editor, Tom Bergeron, for this recognition, and congratulates fellow honorees, including BioNJ President & CEO Debbie Hart, BioNJ members Christopher Cozic (Genmab), Joaquin Duato (Johnson & Johnson), Paul Hudson (Sanofi), and Dr. Jean-Pierre Issa (Coriell Institute for Medical Research), on being named to BINJE’s BEST Health Care 2025 list.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Communications
T: 1 877 TEVOGEN, Ext 701
communications@Tevogen.com